|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021760,
umls-concept:C0030705,
umls-concept:C0205474,
umls-concept:C0332161,
umls-concept:C0376358,
umls-concept:C0392752,
umls-concept:C0445204,
umls-concept:C0449258,
umls-concept:C0597357,
umls-concept:C1450294,
umls-concept:C1704256,
umls-concept:C1749467,
umls-concept:C1883712
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2003-9-26
|
|
pubmed:abstractText |
Several preoperative prostate cancer nomograms have been developed that predict risk of progression using pretreatment prostate-specific antigen (PSA) level, clinical stage, and biopsy Gleason grade. We describe the development and performance of a new nomogram. The nomogram adds new markers to the standard clinical predictors that reflect the biologic behavior of prostate cancer: pretreatment plasma levels of interleukin-6 soluble receptor (IL6SR) and transforming growth factor beta1 (TGF-beta1).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AndrewsBenB,
pubmed-author:CantoEduardoE,
pubmed-author:KattanMichael WMW,
pubmed-author:MatsumotoKazumasaK,
pubmed-author:MuramotoMasatoshiM,
pubmed-author:OhoriMakotoM,
pubmed-author:ScardinoPeter TPT,
pubmed-author:ShariatShahrokh FSF,
pubmed-author:SlawinKevin MKM,
pubmed-author:WheelerThomas MTM,
pubmed-author:ZhuKuichunK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3573-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12913106-Adult,
pubmed-meshheading:12913106-Aged,
pubmed-meshheading:12913106-Aged, 80 and over,
pubmed-meshheading:12913106-Disease Progression,
pubmed-meshheading:12913106-Humans,
pubmed-meshheading:12913106-Male,
pubmed-meshheading:12913106-Middle Aged,
pubmed-meshheading:12913106-Neoplasm Staging,
pubmed-meshheading:12913106-Predictive Value of Tests,
pubmed-meshheading:12913106-Prognosis,
pubmed-meshheading:12913106-Prostate-Specific Antigen,
pubmed-meshheading:12913106-Prostatectomy,
pubmed-meshheading:12913106-Prostatic Neoplasms,
pubmed-meshheading:12913106-Receptors, Interleukin-6,
pubmed-meshheading:12913106-Sensitivity and Specificity,
pubmed-meshheading:12913106-Transforming Growth Factor beta,
pubmed-meshheading:12913106-Transforming Growth Factor beta1,
pubmed-meshheading:12913106-Tumor Markers, Biological
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
|
|
pubmed:affiliation |
Scott Department of Urology, Baylor College of Medicine, 6535 Fannin St, Houston, TX 77030, USA. kslawin@bcm.tmc.edu.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
